Committee Action
On September 19, 2023, the Subcommittee on Health held a
hearing on H.R. 5389. The title of the hearing was ``Examining
Policies to Improve Seniors'' Access to Innovative Drugs,
Medical Devices, and Technology.'' The Subcommittee received
testimony from:
Dora Hughes, MD, MPH, Acting Director,
Center for Clinical Standards and Quality, Acting Chief
Medical Officer, U.S. Centers for Medicare and Medicaid
Services; and,
John Dicken, Director, Health Care--Public
Health and Private Markets, U.S. Government
Accountability Office.
On November 15, 2023, the Subcommittee on Health met in
open markup session and forwarded H.R. 5389, as amended, to the
full Committee by voice vote.
On December 6, 2023, the full Committee on Energy and
Commerce met in open markup session and ordered H.R. 5389, as
amended, favorably reported to the House by a record vote of 46
yeas and 0 nays.
Congressional Budget Office Estimate
Pursuant to clause 3(c)(3) of rule XIII, the following is
the cost estimate provided by the Congressional Budget Office
pursuant to section 402 of the Congressional Budget Act of
1974:
[GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT]
Summary: On December 6, 2023, the House Committee on Energy
and Commerce ordered 41 pieces of legislation to be reported.
This document provides estimates for 21 bills in that package
that are related to health care and consumer protection.
Generally, the bills in this group that would affect direct
spending would:
Limit beneficiary cost sharing for certain
prescription drugs and add certain drugs to the group
of products covered by the Medicare home infusion
benefit;
Prohibit pharmacy benefit managers (PBMs)
from collecting certain fees from prescription drug
manufacturers and require PBMs to provide additional
information to Medicare Part D plans (which provide
prescription drug coverage);
Allow Part D plans more flexibility to add
biosimilar biological products to their formularies and
to change the cost-sharing status of reference
biological products;
Temporarily increase Medicare payment rates
for durable medical equipment (DME); and
Provide mandatory funding for implementation
of certain provisions in several bills.
Estimated Federal cost: The costs of the legislation fall
within budget functions 550 (health) and 570 (Medicare).
Basis of estimate: For this estimate, CBO assumes that the
bills will be enacted near the middle of fiscal year 2024 and
that the estimated amounts will be appropriated each year. This
cost estimate does not include any effects of interactions
among the bills. If all 21 bills were combined and enacted as a
single piece of legislation, the effects could be different
from the sum of the separate estimates.
Direct spending: Enacting 10 bills in the group would
affect direct spending over the 2024-2034 period (see Table 1).
TABLE 1.--ESTIMATED EFFECTS ON DIRECT SPENDING OF HEALTH CARE LEGISLATION, AS ORDERED REPORTED BY THE HOUSE COMMITTEE ON ENERGY AND COMMERCE ON DECEMBER
6, 2023
--------------------------------------------------------------------------------------------------------------------------------------------------------
By fiscal year, millions of dollars--
--------------------------------------------------------------------------------------------------------------------------
2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2024-2029 2024-2034
--------------------------------------------------------------------------------------------------------------------------------------------------------
INCREASES OR DECREASES (-) IN DIRECT SPENDING
H.R. 2880 Budget
Authority................ 0 0 0 -29 -39 -31 -31 -28 -26 -24 -18 -99 -226
Outlays.................. 0 0 0 -29 -39 -31 -31 -28 -26 -24 -18 -99 -226
H.R. 3842 Budget
Authority................ 0 * * * * * * * * * * * *
Outlays.................. 0 * * * * * * * * * * * *
H.R. 4881 Budget
Authority................ 0 0 0 0 77 88 100 106 113 134 136 165 754
Outlays.................. 0 0 0 0 77 88 100 106 113 134 136 165 754
H.R. 5372 Budget
Authority................ 0 -9 -12 -12 -14 -12 -14 -16 -17 -20 -19 -59 -145
Outlays.................. 0 -9 -12 -12 -14 -12 -14 -16 -17 -20 -19 -59 -145
H.R. 5380 Budget
Authority................ 15 0 0 0 0 0 0 0 0 0 0 15 15
Outlays.................. 13 1 1 0 0 0 0 0 0 0 0 15 15
H.R. 5385 Budget
Authority................ 55 0 0 -55 -75 -60 -60 -55 -50 -46 -35 -135 -381
Outlays.................. 49 4 2 -55 -75 -60 -60 -55 -50 -46 -35 -135 -381
H.R. 5386 Budget
Authority................ 0 0 * * * * * * * * * * *
Outlays.................. 0 0 * * * * * * * * * * *
H.R. 5393 Budget
Authority................ 0 6 0 0 0 0 0 0 0 0 0 6 6
Outlays.................. 0 6 0 0 0 0 0 0 0 0 0 6 6
H.R. 5397 Budget
Authority................ 0 0 -9 -13 -15 -14 -15 -17 -17 -20 -19 -37 -139
Outlays.................. 0 0 -9 -13 -15 -14 -15 -17 -17 -20 -19 -37 -139
H.R. 5555 Budget
Authority................ 144 1 0 0 0 0 0 0 0 0 0 145 145
Outlays.................. 144 1 0 0 0 0 0 0 0 0 0 145 145
--------------------------------------------------------------------------------------------------------------------------------------------------------
All amounts for outlays are estimates; except for H.R. 5380 and H.R. 5393, all amounts for budget authority are estimated;
* = between -$500,000 and $500,000.
H.R. 2880, the Protecting Patients Against PBM Abuses Act,
would modify the rules with respect to certain fees that PBMs
collect from prescription drug manufacturers. In Medicare Part
D (which provides prescription drug coverage), sponsors of
private insurance plans contract with the government to deliver
benefits to Medicare beneficiaries. Those insurance plans
usually contract with PBMs to negotiate with drug
manufacturers, design formularies, and perform other
administrative functions. A PBM can be owned by the plan
sponsor or it can be an independent corporate entity.
H.R. 2880 would prohibit PBMs from collecting service fees
from manufacturers that are based on drug prices, manufacturer
discounts, or formulary placement decisions. Under the bill,
those fees would be specific dollar amounts based on the fair
market value of a PBM's services. Under current law, PBMs can
be compensated for services they provide to manufacturers, but
compensation that exceeds the fair market value of a service
must be classified as direct and indirect remuneration and
reported to the Centers for Medicare & Medicaid Services (CMS).
According to the Government Accountability Office, however, CMS
does not routinely monitor how PBMs classify those fees.\1\
Under the bill, CMS and the Office of Inspector General would
more closely monitor those classifications.
---------------------------------------------------------------------------
\1\See Government Accountability Office, Medicare Part D: Use of
Pharmacy Benefit Managers and Efforts to Manage Drug Expenditures, GAO-
19-498 (July 2019), Appendix III, www.gao.gov/products/gao-19-498.
---------------------------------------------------------------------------
CBO estimates that manufacturers' service fees are roughly
1 percent of Part D retail spending under current law. CBO
expects that under H.R. 2880, a portion of those fees would be
reclassified as direct and indirect remuneration by PBMs and,
because of stronger oversight, passed along to the sponsors of
prescription drug plans. That action would reduce bid amounts
for plans' expected benefit payments, which in turn would
reduce spending in Part D. CBO estimates that the provision
would decrease federal spending by $226 million over the 2024-
2034 period, or by roughly 1 percent of the amount expected to
be collected in service fees over that period.
H.R. 3842, the Expanding Access to Diabetes Self-Management
Training Act of 2023, would allow more providers to refer
eligible patients to diabetes self-management training covered
by Medicare and would codify regulatory time limits on use of
the training. CBO expects that enacting H.R. 3842 would result
in more patients receiving such training, which would lead to
increased Medicare spending. CBO expects that such training
would reduce the use of acute-care services, at least partly
offsetting that increase in costs. As a result, CBO estimates
that enacting the bill would increase or decrease direct
spending by less than $500,000 over the 2024-2034 period.
H.R. 4881, a bill to amend title XVIII of the Social
Security Act to limit cost sharing for drugs under the Medicare
program, would limit cost sharing above the deductible to no
more than the average net price for a drug, which is the list
price minus after-sale discounts from the drug's manufacturer.
From 2028 to 2034, CBO projects, less than 1 percent of Part D
spending above the deductible under current law will be for
drugs with cost sharing that exceeds net drug costs. Under the
bill, CBO expects that some out-of-pocket spending by
beneficiaries and some federal subsidies for low-income
beneficiaries would shift onto Part D plans, which would
increase the bids they submit to the federal government to
cover expected benefits spending and therefore increase federal
spending. CBO estimates that enacting H.R. 4881 would increase
direct spending by $754 million over the 2024-2034 period.
H.R. 5372, the Expanding Seniors' Access to Lower Cost
Medications Act of 2023, would allow Part D plans to add
biosimilar biological products to their formularies and change
the cost-sharing status of a reference biological product after
the first 60 days of a plan year. (A reference biological
product is the approved product against which a proposed
biosimilar product is compared.) Under current law, Part D
plans must exempt beneficiaries who currently use reference
biological products from changes in coverage and cost sharing
for the remainder of the year. That restriction limits a plan's
ability to promote use of a biosimilar product immediately
following that product's entry to the market. CMS has proposed
rules that overlap with the bill's provisions concerning
formulary substitutions for biosimilar products.\2\ CBO's
estimate of Medicare spending for those products under current
law accounts for 50 percent of the effect of the proposed
rules. As a result, CBO's estimate of the decrease in direct
spending under H.R. 5372 is larger than it might be if CMS's
rules had become final.
---------------------------------------------------------------------------
\2\See Centers for Medicare & Medicaid Services, ``Medicare
Program; Contract Year 2025 Policy and Technical Changes to the
Medicare Advantage Program, Medicare Prescription Drug Benefit Program,
Medicare Cost Plan Program, and Programs of All-Inclusive Care for the
Elderly; Health Information Technology Standards and Implementation
Specifications,'' Notice of Proposed Rulemaking, 88 Fed. Reg. 78476
(November 15, 2023), http://tinyurl.com/wv7yprfm; and ``Medicare
Program; Contract Year 2024 Policy and Technical Changes to the
Medicare Advantage Program, Medicare Prescription Drug Program,
Medicare Cost Plan Program, Medicare Parts A, B, C, and D Overpayment
Provisions of the Affordable Care Act and Programs of All-Inclusive
Care for the Elderly; Health Information Technology Standards and
Implementation Specifications,'' Notice of Proposed Rulemaking, 87 Fed.
Reg. 79452 (December 27, 2022), http://tinyurl.com/3754c49x.
---------------------------------------------------------------------------
Under the bill, the addition of biosimilar products to
formularies could lead to a shift away from the use of
reference biological products. CBO estimates that the
government will spend about $10 billion over the 2024-2034
period to cover reference biological products under current
law. CBO anticipates that under H.R. 5372 approximately 20
percent of the current use of reference biological products
would be replaced by biosimilar products. The prices for
biosimilar products are estimated to be 15 percent lower, on
average, than the prices for the reference products. Using
information about spending on both types of products under
current law and adjusting for current regulatory proposals by
CMS that would streamline coverage for biosimilar products, CBO
estimates that enacting H.R. 5372 would decrease direct
spending by $145 million over the 2024-2034 period.
H.R. 5380, a bill to amend title XVIII of the Social
Security Act to increase data transparency for supplemental
benefits under Medicare Advantage, would provide $15 million in
2024 for the Department of Health and Human Services (HHS) to
implement reporting requirements for supplemental benefits
under Medicare Advantage plans. Based on historical spending
patterns for HHS programs, CBO estimates that enacting H.R.
5380 would increase direct spending by $15 million over the
2024-2034 period.
H.R. 5385, the Medicare PBM Accountability Act, would
require pharmacy benefit managers to provide plan sponsors with
information not furnished under current law. Part D plans have
access to certain aggregate and drug-specific information from
PBMs concerning prescriptions, prices, rebates, and out-of-
pocket charges, but may lack information about PBM-affiliated
entities and contractors, rationales for formulary decisions,
and explanations for benefit designs that favor certain
pharmacies. H.R. 5385 would require PBMs to report such
information to Part D plans but also, subject to certain
restrictions, would allow plans to audit PBMs' business
practices and request other information. The bill would provide
$55 million for HHS to implement those requirements.
H.R. 5385 also would require PBMs to make their business
practices clearer to Part D plans, thus promoting competition
among PBMs. CBO estimates that the increased competition would
reduce net spending for Part D by less than 0.1 percent over
the 2024-2034 period--reducing federal spending by $436 million
over that period.
CBO estimates that the net effect of the bill would be a
reduction in direct spending of $381 million over the 2024-2034
period.
H.R. 5386, the Cutting Copays Act, would prohibit cost
sharing for generic drugs for beneficiaries who are eligible
for the low-income subsidy, which pays most or all of their
premium and cost-sharing requirements. Under current law, plans
have an option but not an obligation to do so. CBO expects that
enacting the bill would increase the use of generic drugs,
which would increase plan bid submissions for expected benefits
payments and, therefore, federal spending. CBO expects that
some of the increase would be offset by reduced spending on
brand-name drugs and certain medical services. CBO estimates
that enacting the bill would increase direct spending by less
than $500,000 over the 2024-2034 period.
H.R. 5393, a bill to amend title XVIII of the Social
Security Act to ensure fair assessment of pharmacy performance
and quality under Medicare Part D, and for other purposes,
would provide $4 million in in 2025 for CMS program management
to implement pharmacy performance and quality measures for Part
D and $2 million in that year to implement pharmacy
transparency requirements. Based on historical spending
patterns for CMS administrative costs, CBO estimates that
enacting H.R. 5393 would increase direct spending by $6 million
over the 2024-2034 period.
H.R. 5397, the Joe Fiandra Access to Home Infusion Act of
2023, would add drugs to the current Medicare benefit that
allows patients to receive some drugs by infusion under nursing
care at home. H.R. 5397 would allow other drugs to meet the
statutory criteria for coverage in the home setting by
establishing those products as suitable for delivery through a
pump and requiring patients receiving those drugs also to
receive regular nursing services.
Based on its analysis of the beneficiary population and
Medicare payment rates, CBO estimates that enacting the bill
would reduce direct spending by $139 million over the 2024-2034
period, primarily because beneficiaries would bear a larger
share of the cost of infusions that occur at home. Under
current law, there is a cap on beneficiary cost sharing in
outpatient hospital settings, which is where CBO expects that
beneficiaries receive those drugs now. There is no equivalent
cap for the home infusion benefit.
CBO's estimate for H.R. 5397 is subject to considerable
uncertainty. First, it is not known how many drugs would
qualify for coverage under the bill. CBO's estimate focused on
three products that industry and clinical experts mentioned as
likely candidates, but the actual number could be larger or
smaller. In addition, given that cost sharing could increase
significantly for patients, it is not known how many
beneficiaries would choose to receive home infusions.\3\
---------------------------------------------------------------------------
\3\CMS proposed a similar but not identical policy in a proposed
rulemaking. In the regulatory impact analysis, CMS estimated that, for
one product, beneficiaries' cost sharing would be about triple the
amount if the product was received in a home setting. For more
information, see Centers for Medicare & Medicaid Services, ``Medicare
Program; Durable Medical Equipment, Prosthetics, Orthotics, and
Supplies (DMEPOS) Policy Issues and Level II of the Healthcare Common
Procedure Coding System (HCPCS),'' Notice of Proposed Rulemaking, 85
Fed. Reg. 70358 (November 4, 2020), http://tinyurl.com/29djdrvz.
---------------------------------------------------------------------------
H.R. 5555, the DMEPOS Relief Act of 2023, would temporarily
increase Medicare rates in some areas of the country for DMEPOS
(durable medical equipment, prosthetics, orthotics, and
supplies). Under current law, Medicare's payments for some
equipment are based on competitive bidding among suppliers. CMS
uses those results to set rates (either directly or through a
blend with the historic fee schedule) in areas of the country
where formal bidding has not occurred. Prior legislation
directed CMS to use a blend of fee schedule and competitively
bid rates in some areas of the country; the use of those
blended rates expired at the end of calendar year 2023.
Enacting H.R. 5555 would extend the use of those blended rates
thro